Tony b,As per quarterlyIn FY24 Neurotech anticipates:1)HREC...

Tony b,

As per quarterly

In FY24 Neurotech anticipates:

1)HREC approval for a Phase I/II clinical trial in paediatric spastic cerebral palsy (Q3 FY24)
2)Results of the Phase I/II Rett Syndrome clinical trial (Q3 FY24)
3)Results of the Phase II/III ASD clinical trial (Q3 FY24)
4)Orphan Drug Designations (ODDs) for NTI164 in PANDAS/PANS with US and EU regulatory bodies

All of the above look to be coming this quarter -- Q3 FY24 being Q1 CY24, so they are due within the next 2 months

And a snippet from Professor Dale , regarding our Pandas Pans trial, in the quarterly also:

"I have observed quite profound improvements in a number of my patients with NTI164, making it the first trial of its kind with a broad-spectrum cannabinoid therapy showing initial clinical utility like this with excellent safety. In addition, we await furtherevidence of genomic molecular changes from baseline measures and after 12 weeks of treatment to correlate this meaningful clinical response we have seen with biological evidence of effect. This would be a major step-forward for PANDAS/PANS patients and assist in identifying relevant biomarkers of the disease.”

Note " we await further evidence"

Hopefully there is further news coming on this "major step-forward"

Our significant re rate is coming.

Just cheap - real cheap.